Medications for Nonradiographic Axial Spondyloarthritis

5 results
  • bimzelx - bimekizumab injection, solution

    (Bimekizumab)
    Ucb, Inc.
    BIMZELX treats adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis with objective signs of inflammation, and moderate-to-severe hidradenitis suppurativa.
  • cimzia - certolizumab pegol

    (Certolizumab Pegol)
    Ucb, Inc.
    CIMZIA is a TNF blocker that treats moderately to severely active Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis in adults, and polyarticular juvenile idiopathic arthritis in patients 2 years and older.
  • cosentyx - secukinumab injection

    (Secukinumab)
    Novartis Pharmaceuticals Corporation
    Cosentyx treats moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and moderate-to-severe hidradenitis suppurativa in eligible adults and pediatric patients.
  • rinvoq - upadacitinib tablet, extended release

    (Upadacitinib)
    Abbvie Inc.
    RINVOQ is a JAK inhibitor indicated for adults and some pediatric patients with rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis, generally after inadequate response to TNF blockers.
  • taltz - ixekizumab injection, solution

    (Ixekizumab)
    Eli Lilly And Company
    TALTZ treats moderate-to-severe plaque psoriasis in patients 6 and older who are candidates for systemic therapy or phototherapy, and in adults with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis with objective signs of inflammation.